ClinicalTrials.gg
RecruitingNCT02704520TRIGGERUpdated Oct 17, 2024

Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial

An interventional study of High resolution MRI scan and mrTRG assessment in Rectal Cancer, sponsored by Imperial College London. Recruiting at 10 sites in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Imperial College London · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2016; still recruiting 10 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
441
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Rectal Neoplasms with a site in United Kingdom — 16 open to participants now, 26 under way, 5 of them phase 3. Rectal Neoplasms · United Kingdom.

Planned enrollment
19th of 78
441 · median 115
Started
2016
with 2 others
No phase
26 of 113
6 open now
Primary completion
2026-12
later than 12 of 25 live
Registered
72nd of 113
by date
Lead sponsor
9 of 113
Imperial College London

Among the 113 studies in Rectal Neoplasms with a site in United Kingdom, this one is the 19th largest by planned enrollment of the 78 interventional ones that give a count, is one of 3 that started in 2016, is one of 26 with no phase, reaches primary completion later than 12 of the 25 other live ones, and was the 72nd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

16 of the 113 studies in Rectal Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Rectal Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

Open to patients undergoing any pre-operative treatment for locally advanced rectal cancer, TRIGGER is the only phase III clinical trial in the UK offering watch and wait. All patients will have post treatment MRI scans routinely performed, no change from the MERCURY trials high resolution MRI protocol is required. Patients will be randomised to either the control arm for management according to national guidelines - conventional MDT, clinical assessment post-treatment planning using the baseline MRI. Patients in the interventional arm will have their post treatment MRI scans read by a radiologist trained and supported to reliably report the mrTRG grade and have their management directed accordingly - 'Good response' (mrTRG 1\&2) - watch and wait (avoidance of surgery) offered. 'Poor response' (mrTRG 3-5) - local colorectal MDT is informed and uses information to discuss and agree next steps in treatment and surveillance. Patients are followed up for five years with QoL questionnaires completed at registration, 3 and 5 years.

Read the detailed description

The only phase III clinical trial in the UK offering watch and wait, the TRIGGER trial aims to validate mrTRG as an imaging biomarker for the stratified management of patients with locally advanced rectal cancer. The 'good responders' (mrTRG1\&2) often have no evidence of tumour and it may be possible to avoid surgery in this group and so maintaining QoL while not impacting survival rates. The 'poor responders' (mrTRG3-5) are at high risk of poor oncological outcomes and this knowledge is useful in planning ongoing treatment and surveillance.

TRIGGER is now a non-cTIMP trial as the protocol does not specify chemotherapy or IMP treatments. Decisions about the use of chemotherapy will be based upon local MDT discussions as is normal practice and national policy and the trial CRFs will capture these decisions and whether more treatment is given to patients or not. TRIGGER does not mandate or recommend the use of any treatments: specifically it does not suggest the use of investigational medicinal products. If any centre wishes to use IMPs this would be in the context of separate trial protocols and would not preclude entry into TRIGGER.

03

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Rectal Cancer
  • Magnetic Resonance Imaging
  • Chemoradiotherapy
  • Chemotherapy
  • Diagnostic Imaging
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. MRI defined locally advanced rectal carcinoma i.e. one or more: greater than or equal to mrT3c; mrEMVI positive; mr N1c; mr CRM positive
  2. confirmed adenocarcinoma of radiologically defined rectum
  3. Be deemed to require preoperative chemoradiotherapy (CRT) or total therapy (TNT)

Exclusion criteria

Exclusion Criteria:

  1. disease
  2. MRI, radiotherapy and/or chemotherapy
  3. A post-treatment MRI performed more than 10 weeks after the completion of radiotherapy if given
  4. Previous within preceding 5 years if risk of recurrence >5%
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
441 participants (estimated)

Study arms

  • Other
    Control arm

    Management according to national guidelines - conventional MDT, clinical assessment post-treatment planning

    Diagnostic Test: High resolution MRI scan

  • Experimental
    Intervention arm

    mrTRG directed management 'Good response' (mrTRG 1\&2) - deferral of surgery (watch \& wait) offered. 'Poor response' (mrTRG 3-5) - local colorectal MDT is informed and uses information to discuss and agree next steps in treatment and surveillance.

    Diagnostic Test: High resolution MRI scan · Diagnostic Test: mrTRG assessment

Interventions

  • Diagnostic testHigh resolution MRI scan

    MRI reporting of tumour but not mrTRG in the control arm = standard of care

  • Diagnostic testmrTRG assessment

    Watch and wait offered for good responders Consider further treatment for poor responders

06

What researchers measure

Primary outcomes

  1. To show that patients can successfully avoid surgery after achieving a good response to treatment as measured on MRI (mrTRG).

    Non-inferiority of overall survival at 3 years for the mrTRG (MRI Tumour Regression Grade) good response group (mrTRG 1 and 2) compared with control.

    Time frame: Up to 5 years

Secondary outcomes

  1. To describe the prognostic features associated with good and poor response to treatment as measured by MRI (mrTRG)

    Correlation of baseline and post treatment prognostic factors on imaging and pathology against survival outcomes

    Time frame: 3 years and 5 years

  2. To show mrTRG (Tumour Regression Grade) as a measurement tool can be reproduced by appropriately trained radiologists.

    Agreement between local and centrally measured mrTRG (MRI Tumour Regression Grade) (mrTRG 1 good to mrTRG 5 poor)

    Time frame: Up to 2 years

  3. Surgical morbidity

    Comparison by arm of early (30 day) surgical morbidity according to the Clavien-Dindo classification.

    Time frame: 30 days post operative

  4. Surgical morbidity

    Comparison by arm of late (up to 12 months) surgical morbidity according to the Clavien-Dindo classification.

    Time frame: 12 months post operative

  5. To investigate the effect of the preoperative treatment regime on mrTRG measurement

    Reporting of treatment given against measurement of mrTRG (MRI Tumour Regression Grade) response (mrTRG 1 good to mrTRG 5 poor)

    Time frame: Up to 2 years, 3 years and 5 years

  6. To investigate the effect of the preoperative treatment regime on survival outcomes

    Reporting of treatment given survival outcomes

    Time frame: Up to 2 years, 3 years and 5 years

  7. To investigate the effect of mrTRG directed treatment strategy on Quality of Life

    Quality of life assessed using EORTC QLQ-C30, EQ-5D and Low Anterior Resection Syndrome Score (LARS).scans performed at baseline, post-CRT and during surveillance schedule.

    Time frame: 1 year, 2 years, 3 years and 5 years

  8. To investigate the economic impact of introducing an mrTRG directed treatment strategy

    Healthcare costs using NHS Reference Costs combined with health resource utilization and QoL data

    Time frame: Up to 2 years, 3 years and 5 years

  9. To define molecular and immunological characteristics associated with treatment response as measured by MRI (mrTRG).

    Correlate molecular and immunological biomarkers with outcome measures of mrTRG (MRI Tumour Regression Grade) response, (mrTRG 1 good to mrTRG 5 poor) and survival outcomes

    Time frame: Up to 2 years, 3 years and 5 years

  10. To assess whether the detection of ctDNA predicts for relapse in patients with locally advanced rectal cancer

    Correlate ctDNA levels with outcome measures of mrTRG (MRI Tumour Regression Grade) (mrTRG 1 good to mrTRG 5 poor) and survival outcomes

    Time frame: Up to 2 years, 3 years and 5 years

07

Study locations

10 of 10 sites recruiting
08

References and documents

Publications

  • Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, Moran BJ, Khakoo S, Tekkis P, Rasheed S, Mirnezami A, Quirke P, West NP, Nagtegaal I, Chong I, Sadanandam A, Valeri N, Thomas K, Frost M, Brown G. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials. 2017 Aug 29;18(1):394. doi: 10.1186/s13063-017-2085-2. PubMed 28851403 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2016 (actual). Primary completion is estimated for Dec 2026, 129 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 129 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2016
First posted
Mar 10, 2016
StartActual
Mar 2016
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2036
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02704520
Responsible party
Sponsor
First posted
Mar 10, 2016
Start date
Mar 2016
Primary completion
Dec 2026 (estimated)
Completion
Dec 2036 (estimated)
Last update
Oct 17, 2024

Study contacts

Caroline Martin
Contact
cmartin1@imperial.ac.uk
+44 (0) 7749 655 817
Syvella Ellis
Contact
giclinicaltrials@imperial.ac.uk
+44 (0) 7732 315 234
Gina Brown, MD
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion